Physician profile
Tara Devoy
NPI 1801184684
$2,201.02
in general payments reported to CMS, 2019-2025
15 companies · $748 in 2025
The $748 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $301 · 2023: $455 · 2024: $319 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.15 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $424.59 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $207.49 | 2022-2025 | Fasenra, Farxiga |
| Novartis Pharmaceuticals Corporation | $198.49 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $179.64 | 2021-2022 | |
| Pfizer INC. | $138.72 | 2022-2025 | |
| Amgen INC. | $104.32 | 2024-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $81.38 | 2023 | Verquvo |
| Lilly USA, LLC | $63.16 | 2025 | Zepbound |
| Boston Scientific Corporation | $43.09 | 2024-2025 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $40.74 | 2025 | Onpattro |
| Novo Nordisk INC | $26.53 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $19.63 | 2024 | Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $18.13 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.96 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Devoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.